期刊
CELL COMMUNICATION AND SIGNALING
卷 18, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12964-020-0527-z
关键词
STAT3; Breast cancer; Oncogene; Small molecule inhibitors
类别
资金
- Shandong Provincial Natural Science Foundation [ZR2019MH001]
- National Natural Science Foundation of China [81803562, 81273532]
- Fundamental Research Funds for the Central Universities [2019ZRJC004]
Breast cancer has grown to be the second leading cause of cancer-related deaths in women. Only a few treatment options are available for breast cancer due to the widespread occurrence of chemoresistance, which emphasizes the need to discover and develop new methods to treat this disease. Signal transducer and activator of transcription 3 (STAT3) is an early tumor diagnostic marker and is known to promote breast cancer malignancy. Recent clinical and preclinical data indicate the involvement of overexpressed and constitutively activated STAT3 in the progression, proliferation, metastasis and chemoresistance of breast cancer. Moreover, new pathways comprised of upstream regulators and downstream targets of STAT3 have been discovered. In addition, small molecule inhibitors targeting STAT3 activation have been found to be efficient for therapeutic treatment of breast cancer. This systematic review discusses the advances in the discovery of the STAT3 pathways and drugs targeting STAT3 in breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据